Cytori Licensee Kerastem Tech Expands
Phase II Trial Of Early Baldness
January 21, 2016, 07:31:00 AM EDT By RTT
News
 |
| Shutterstock photo |
(RTTNews.com) - Cytori Therapeutics, Inc.
( CYTX ) Thursday said that its licensee Kerastem Technologies, LLC, has expanded
STYLE, its US phase II clinical trial. Kerastem said it has added new trial
sites in New York and New Jersey to complement the currently enrolling sites in
Los Angeles and Miami. The trial in phase II is to investigate early stage
female and male pattern hair loss or alopecia.
Marc Hedrick, president & CEO of
Cytori said, "If this trial is successful, we believe the Kerastem/Cytori
partnership could provide effective treatment for people dealing with hair loss
and create a significant new revenue source for Cytori, creating value for our
stockholders."
STYLE is a randomized, blinded,
and controlled investigation of Kerastem it was approved to enroll up to 70
patients at up to eight centers within the United States.
